SCHEDULE 14A INFORMATION

  Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of
                                      1934
                                (Amendment No. )

Filed by the Registrant [ ]

Filed by a Party other than the Registrant [X]

Check the appropriate box:

                                          [_]Confidential, for Use of the
[_]Preliminary Proxy Statement              Commission Only (as Permitted by
                                            Rule 14a-6(e)(2))

[_]Definitive Proxy Statement

[_]Definitive Additional Materials

[X]Soliciting Material Pursuant to (S)240.14a-11(c) or (S)240.14a-12


                                  Pfizer, Inc.
             -----------------------------------------------------
               (Name of Registrant as Specified In Its Charter)


                              Pharmacia Corporation
             -----------------------------------------------------
   (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X]No fee required.

[_]$125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2) or Item
   22(a)(2) of Schedule 14A.

[_]$500 per each party to the controversy pursuant to Exchange Act Rule 14a-
   6(i)(3).

[_]Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

  (1) Title of each class of securities to which transaction applies:

  (2) Aggregate number of securities to which transaction applies:

  (3) Per unit price or other underlying value of transaction computed pursuant
    to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is
    calculated and state how it was determined):

  (4) Proposed maximum aggregate value of transaction:

  (5) Total fee paid:

[_]Fee paid previously with preliminary materials.

[_]Check box if any part of the fee is offset as provided by Exchange Act Rule
   0-11(a)(2) and identify the filing for which the offsetting fee was paid
   previously. Identify the previous filing by registration statement number, or
   the Form or Schedule and the date of its filing.

  (1) Amount Previously Paid:




  (2) Form, Schedule or Registration Statement No.:

  (3) Filing Party:

  (4) Date Filed:

Notes:





2002 July 15


Dear Global Leadership Team Colleagues:

You will see this morning a press release regarding the planned acquisition of
Pharmacia by Pfizer, and also a Talking About Our Business message to all our
people giving a perspective and management direction on this major decision.

I am writing to you, our top managers worldwide, to ask that together we step up
to the challenge of leading our people in this time of dramatic and stressful
change.

Beginning today, your people will be looking to you. Their morale and sense of
direction will be guided by what you say. Even more, they will be guided by what
you do and how you behave.

I know that many of you may be feeling uncertainty and stress. Many will be
worried about your own jobs, the possible impact on your families and on the
people who work for you or are part of your network at Pharmacia.

These are normal feelings in such times of uncertainty.

However, as I state in my message to all of our people, it is easy to get into a
gridlock situation where people become paralyzed with rumors and anxiety about
what will happen and lose sight of their primary mission.

                                                                               1



We cannot allow this to occur.

The work we do is too important. Doctors and patients are counting on us.
Further, work paralysis of this type will only damage future opportunities for
the company and individual employees.

As leaders we must therefore look outside ourselves and do the right thing. We
must continue high-performance at Pharmacia over the next months, and to build
the strengths of Pharmacia into the combined company when it is created.

We must truly care for our people and show that we care. We must provide them
with factual information - empathize with them and help them manage their
anxiety. We should help them avoid an attitude of gloom and doom - yet we must
not create expectations for which there is no basis.

By acting on this agenda, our people will continue to trust us and follow our
lead, in a time of great uncertainty and change. It will also help us to curb
the "exit syndrome" of valuable people leaving the organization due to fear and
uncertainty or simply "shutting down" on their jobs.

The way we act upon these priorities is key. I ask us all more than ever to
demonstrate the Pharmacia Way of working, and our best-managed behaviors.

In particular, I ask us all to operationalize our Pharmacia values (4Cs).

                                                                               2



     o   Commitment. Be committed to our goals and Pharmacia, and commit to an
         open mind and positive attitude about the acquisition process. Our
         people will want to see your continued pride and confidence about the
         good company we have built at Pharmacia. This requires courage in the
         face of our own doubts and concerns.

     o   Competence. Continue to lead the way by doing your job exquisitely
         well. This will help us to continue to deliver high performance for our
         stakeholders. It will set a positive model for your people. And it is
         the best way to demonstrate our value to the new company.

     o   Consistency. Especially in this time of change, show your people that
         your expectations of them, and your concern for them, do not change.
         Also demonstrate to your people that your own behavior remains
         consistent, even when there is unusual stress.

     o   Compassion. Your people will be feeling fragile and vulnerable. Take
         extra time to show them that you understand their concerns, and that
         you empathize with them. At the same time we must be very careful not
         to fall into a demoralizing spiral of commiseration. We must also be
         very careful not to make promises about outcomes that are still
         unknown.

We have a great cadre of leaders who constitute our Global Leadership Team. I
know that during this very challenging time, we can count on you to exercise the
common sense, good judgment, and leadership skills that you have applied so
effectively over the past years together.

                                                                               3



Let me also thank you sincerely for your hard work, your professionalism, and
your support. You continue to make me very proud to be a part of Pharmacia.

Sincerely,

Fred Hassan
Chairman and Chief Executive Officer

================================================================================

Note from Global Internal Communications: please refer to the Leadership Toolbox
for a comprehensive set of materials intended to help you begin the process of
helping your people through this long-term change.



                      GUIDELINES FOR LEADERS - 2002 JULY 15
                        PFIZER'S ACQUISITION OF PHARMACIA


Now more than ever before, your people will be looking to you as a leader. Their
morale and sense of direction will be guided by what you say and do, how you
manage change and conduct yourself.

Pharmacia leaders are men and women of integrity, thoughtfulness and decisive
action. Following are some guidelines to help you focus on your responsibilities
as leaders of this organization:

                        OPERATIONALIZING PHARMACIA VALUES

o    Commitment. Be committed tour goals and Pharmacia, and commit to an open
     mind and positive attitude about the acquisition process. Our people will
     want to see your continued pride and confidence about the great company we
     have build at Pharmacia. This requires courage in the face of our own
     doubts and concerns.

o    Competence. Continue to lead the way by doing your job extremely well. This
     will help us to continue to deliver high performance for our stakeholders.
     It will set a positive model for your people.

o    Consistency. Especially in this time of change, show your people that your
     expectations of them, and your concern for them, do not change.

o    Compassion. Your people will be feeling fragile and vulnerable. Take time
     to show them that you understand their concerns, and that you empathize
     with them. At the same time we must be very careful not to fall into a
     demoralizing spiral of commiseration. We must also be very careful not to
     make promises about outcomes that are still unknown. For example, it is not
     true compassion to promise people not to worry about their job security,
     when we simply do not yet know the integration details.


                            COMMUNICATING ACCURATELY

o    Provide an opportunity for focused discussion among your employees.

o    Be factual in your answers to questions.

o    Do not provide speculative answers when no clear details exist.




o    Be comfortable in saying: "I don't know."

o    Reassure your people that as you learn information, you will share it
     openly with them.

o    Avoid making statements that could be misconstrued as a promise or which
     create expectations of a guaranteed outcome.

o    Allow some time for your people to vent their emotions; then lead your
     group discussion toward positive interaction.

o    Remember that Pfizer and Pharmacia remain competitors until the deal closes
     later this year, and must conduct business as such. Therefore, please
     caution your team not to share competitive information with their Pfizer
     counterparts or other employees or representatives of Pfizer.




                           KEY MESSAGES - 2002 JULY 15
                        PFIZER'S ACQUISITION OF PHARMACIA


o    Pfizer, Inc. has announced its intention to acquire Pharmacia by means of a
     merger of a new subsidiary of Pfizer into Pharmacia. The name of the
     combined company will be Pfizer, Inc. This will create the largest and
     strongest pharmaceutical company in all major regions of the world.

o    Pfizer will exchange 1.4 shares of its stock for each share of Pharmacia
     stock. This reflects a 52% premium over the closing price of the companies'
     stock price on Friday, after excluding the value of Pharmacia's Monsanto
     stock that will be spun-off before the merger. The deal still must be
     approved by various regulatory authorities and also by a vote of
     shareholders of both companies.

o    The expectation is that the deal will close in late 2002.

o    Since the dramatic turnaround of Pharmacia & Upjohn in 1998 and the merger
     with the original Monsanto in 2000, we succeeded in creating a company
     characterized by strong, central research and marketing and a powerful U.S.
     operation with growing strength in global markets. We have transformed
     former niche products such as Detrol, Xalatan and Camptosar into major
     products. Our scientists have developed Zyvox, the first antibiotic in a
     completely new class in 35 years. And Pharmacia decisively pulled ahead of
     Merck as the global leader with our COX-2 franchise.

o    In spite of these successes and our potential to continue as an independent
     company, we faced an increasingly challenging business environment. In the
     past, we rejected approaches from other companies, including Pfizer. We
     considered a number of alternatives. A merger of equals, or the takeover of
     another company by Pharmacia, would not have been realistic today. The cost
     and value erosion would have been more than our shareholders would accept.
     When Pfizer made this offer - one of the highest premiums ever paid for a
     major acquisition - Pharmacia's Board felt compelled to accept it. As
     required by Delaware law, the Board was required to take the action it
     deemed to be in the best interests of the company and its shareholders.
     This transaction creates significant additional value for our shareholders,
     including employees who own stock through the company's compensation plans.

o    Pharmacia's Chairman and CEO Fred Hassan will serve as Vice Chairman of
     Pfizer and be a member of its Board of Directors.

                                                                               1



o    Pfizer's current leadership team will guide the course of the combined
     company.

o    At this point, no plans have been set and no decisions have been made about
     the integration of Pharmacia into Pfizer. However, we do expect that
     Pharmacia employees will be asked to work with our Pfizer counterparts on
     integration plans. After the merger, many Pharmacia people will continue in
     their work. Others may be asked to change their roles, or there may not be
     roles for them at all in the new organization. Pfizer has agreed that all
     Pharmacia compensation and benefit plans will be honored after the merger
     and will provide comparable benefits for two years after the merger.
     Pharmacia people need to stay on task, focused on our work, and maintain
     pride in our professionalism and our ability to deliver on the expectations
     of physicians and patients around the world.

o    Pharmacia leaders have committed to providing all employees with
     information about the transaction as it unfolds. They have expressed pride
     publicly in the caliber of Pharmacia people and in our accomplishments.






                                                                               2




                      QUESTIONS AND ANSWERS - 2002 JULY 15
                        PFIZER'S ACQUISITION OF PHARMACIA


THE TRANSACTION
- ---------------

QUESTION:  WHAT KIND OF TRANSACTION IS THIS? A MERGER OR AN ACQUISITION?
Answer: This is a transaction in which Pfizer will acquire Pharmacia
Corporation. This is not a merger of equals. However, the acquisition will be
effected by merging a newly created subsidiary of Pfizer into Pharmacia.


Q:  WHAT PRICE WILL PFIZER PAY FOR PHARMACIA?
A: The price will be 1.4 shares of Pfizer stock for each share of Pharmacia.
This represents a 52 percent premium on Pharmacia's pharmaceutical stock price
as of the close of business on Friday, July 12, and a 44 percent premium on a
30-day basis.

Pharmacia's Monsanto shares will be spun-off to Pharmacia shareholders before
the merger, so each current Pharmacia share will be converted into part of a
Monsanto share and 1.4 shares of Pfizer.

This large premium reflects Pfizer's confidence in the quality of Pharmacia as a
company.


Q:  WHEN WILL THE ACQUISITION OCCUR?
A: The external announcement of Pfizer's intention to acquire Pharmacia was made
on July 15 at 6 a.m. Eastern Daylight Time. In that announcement, Pfizer's
leadership estimated that the deal would close late in 2002, subject to approval
by shareholders of both companies, necessary governmental and regulatory
approvals and other normal closing conditions.


Q:  WHAT DOES THIS MEAN FOR PHARMACIA EMPLOYEES?
A: Now that the acquisition has been announced, you will read and hear a lot of
news and commentary in the media about the impact of the transaction. That
commentary also will include talk of cuts in programs and people. However, the
two companies have not yet begun to develop plans for integrating Pharmacia into
Pfizer. Although we can expect major changes, we must base our actions and
decisions on facts, not on rumors or speculation by outside commentators.
Pharmacia leaders will continue to keep Pharmacia employees informed about the
transaction and integration plans as they unfold. However, Pharmacia people must
realize that once the acquisition closes, Pfizer will determine the strategies
and make the business decisions for the combined company.


                                                                               1


Q: WHAT SHOULD WE BE DOING DURING THE TIME BETWEEN THIS ANNOUNCEMENT AND WHEN
THE DEAL CLOSES?
A: We can and should focus on what we do control. That includes the quality of
our work and the benefits to patients and doctors that our products provide and
that our research and development promises.

Because the merger is subject to shareholder approval, regulatory approval and
other conditions to closing, there is always a chance that the merger may not
occur. Further, until the merger is completed, Pharmacia and Pfizer will remain
competitors and should continue to maintain their separate business directions.

Whether or not the merger occurs, the best thing we can do for ourselves and our
customers and patients during this time of transition is to continue to do the
best job we can at our current tasks.


Q:  HOW WILL THE ACQUISITION AFFECT PHARMACIA'S STOCK PRICE?
A: Only the market can answer that question, and it will fluctuate over time.
However, the price of Pharmacia stock will begin to trade near the price equal
to 1.4 shares of Pfizer stock as completion of the merger nears and becomes more
certain. Until the deal closes, Pharmacia will continue to be traded as a public
company.


Q:  HOW DOES THE ACQUISITION OF PHARMACIA AFFECT OUR SPIN-OFF OF MONSANTO?
A: As we announced today, we intend to complete the spin-off of Monsanto as soon
as practicable. We expect to complete the spin-off before Pfizer acquires
Pharmacia. The proposed merger with Pfizer had no impact on the decision or
timing to spin-off our Monsanto shares. For more information about the Monsanto
spin-off, please see related key messages and questions and answers on the
Leadership Toolbox under that topic heading.


THE IMPACT
- ----------

Q:  WHO IS RESPONSIBLE FOR MAKING THE DECISION ABOUT THIS TRANSACTION?
A: Pharmacia's Board of Directors was required to decide whether or not to
accept Pfizer's offer. The Board approved the transaction on Saturday, July 13.


                                                                               2


Q:  WHY DID PHARMACIA AGREE TO A TAKEOVER BY PFIZER?
A: Recent growing pressures in our industry have caused all large companies to
re-think their business models. In the past, we had rejected informal approaches
from various companies. When Pfizer approached us with an offer that we viewed
as compelling for our shareowners, we concluded that we should accept it. Under
Delaware law that governs the company, Pharmacia's Board was required to take
the action it deemed to be in the best interests of the company and its
shareholders. The Board determined that the Pfizer offer would create more value
for shareholders than any other alternative. Alternatives such as a merger of
equals, takeover of another company by ourselves or remaining independent would
not have provided such a significant enhancement of shareholder value.


Q:  HOW WILL THE ACQUISITION IMPACT OUR MOVE TO BASKING RIDGE?
A: Plans around our move to Basking Ridge have been placed on hold until Pfizer
provides further clarification and direction about its interest in the property.


Q:  WHO WILL THE POST-TRANSACTION MANAGEMENT TEAM INCLUDE?
A: As noted in the announcement about the acquisition, Pharmacia Chairman and
Chief Executive Officer Fred Hassan will be named Vice Chairman of Pfizer and a
member of the Pfizer Board of Directors upon the close of the transaction. Other
management decisions have yet to be made, but it's important to acknowledge that
Pfizer's current leadership team will primarily be guiding the course of the
combined company.


Q:  HOW MUCH WILL PHARMACIA'S LEADERS MAKE ON THIS DEAL?
A: Members of management make no special compensation as a result of this deal.
However, as shareholders of Pharmacia stock, Pharmacia's leaders will enjoy the
same benefits as all stockholders, whether they are Pharmacia employees,
individual or institutional investors. In the event management or other
employees are terminated as a result of the merger, special severance
compensation and benefits will be provided as disclosed separately.


                                                                               3



Q:  HOW WILL THE ACQUISITION AFFECT PHARMACIA EMPLOYEES' JOBS?
A: There will be no immediate changes or impacts. It is important for all
Pharmacia people to continue to focus on their current tasks and to maintain
existing reporting relationships. Because the merger is subject to shareholder
approval, regulatory approval and other conditions to closing, there is always a
chance that the merger may not occur. Further, until the merger is completed,
Pharmacia and Pfizer will remain competitors and should continue to maintain
their separate business directions. We need to keep doing what is right for our
customers and our patients, and what is right for our business. As Pharmacia
people, we are accustomed to change. We can take pride in our ability to
function even in a time of change and uncertainty.


Q: WHAT ARE WE TELLING OUR CUSTOMERS, OUR SHAREOWNERS AND THE PATIENTS WHO RELY
ON PHARMACIA FOR MEDICATIONS?
A: Pfizer's announcement of its intention to acquire Pharmacia is now public
knowledge. Our customers, shareowners and patients have access to that
information. They will very likely have questions for the Pharmacia people with
whom they deal on a regular basis. We can assure them that Pharmacia will
continue to operate as the world-class pharma company it is now and throughout
the transition.


Q: WHY IS THE PHARMACIA MANAGEMENT TEAM GIVING UP ON OUR VISION TO BE A
WORLD-CLASS PHARMACEUTICAL COMPANY?
A: We continue to be passionate in our commitment to improving health and
wellness around the world. In fact, it is because of our vision and achievement
in carrying it out that our company is an attractive partner for Pfizer.
Pharmacia is widely recognized as a best-managed company with innovative
medicines, products and services. We have delivered best-managed performance for
our shareowners and by joining Pfizer we can continue to achieve superior
long-term growth and profitability.


                                                                               4



Q: FRED HASSAN TOLD US EARLIER THIS YEAR THAT WE HAD TWO STRATEGIC IMPERATIVES:
"DO MORE WITH WHAT WE HAVE" AND "BUILD STRENGTH ON THE INSIDE SO WE CAN MANAGE
WHATEVER HAPPENS ON THE OUTSIDE." HOW DOES THIS ACQUISITION ALIGN WITH THOSE
STRATEGIC IMPERATIVES?
A: Those were the right strategic imperatives for as long as we remained an
independent company.

We have built exceptional strength within our organization. Pharmacia achieved
exceptional milestones this year with the launch of Bextra, the Celebrex label
change by the FDA and the planned launch of eplerenone later this year.

In addition, we have achieved outstanding results by doing more with what we
have. Pharmacia people conducted themselves admirably in achieving savings
through their hearty endorsement of the SMART initiatives and have taken
numerous actions to embed cost consciousness throughout the organization.

The combined company will be better able to respond to the growing R&D risks and
competitive pressures on our industry.


Q: WHEN THE SMART INITIATIVE WAS ANNOUNCED, PHARMACIA LEADERSHIP TOLD EMPLOYEES
THAT IT WAS NOT INTENDED AS PREPARATION FOR A MERGER. WHAT CHANGED?
A: The SMART initiative was not undertaken in preparation for a merger. What
changed were the industry environment and the offer from Pfizer. Nothing has
changed relative to our SMART initiative or the policies that have been enacted
as a result of our effort to reduce costs and embed cost consciousness in our
way of doing business. They continue to be in force. When the SMART program was
introduced earlier this year, the leadership team had no plans to enter into any
kind of transaction with another company. Now that we have, we will continue to
work diligently to reduce spending.


PERSONAL CONCERNS
- -----------------

Q:  WILL I STILL HAVE A JOB WITH PFIZER?
A: We don't know. The companies have not begun to consider integration plans.
It's difficult to estimate how many jobs will be available at Pfizer following
the close of this transaction - and that's Pfizer's decision. We expect that a
significant number of Pharmacia employees will be offered positions at Pfizer.


                                                                               5



Q: IF I'M ONE OF THE PEOPLE WHO LOSE MY JOB, WILL I BE OFFERED A SEVERANCE
PACKAGE?
A: Yes. On a global basis, all Pharmacia severance and redundancy plans will be
fully honored. A separate communication on these programs will be forthcoming.


Q:  CAN YOU EXPLAIN SOME OF THE DETAILS OF THE U.S. SEPARATION PLAN?
A: In the event of an acquisition, base pay and the annual incentive bonus are
used to calculate the severance benefit. This is a new provision of the
separation benefit plan for U.S. employees that isn't reflected in materials
distributed earlier this year. The merger agreement also calls for severance pay
to be provided to employees who voluntarily leave the company if they're
requested to relocate to another state or more than 50 miles.


Q: WHAT WILL HAPPEN TO MY HEALTH INSURANCE AND OTHER BENEFITS IF I LOSE MY JOB?
A:  The terms and conditions of your existing health insurance plans will apply.

U.S. employees under the separation benefit plan will be eligible to continue
health benefits at active employee rates for the first six months of coverage
following their employment termination date. For the next 12 months, they will
be able to continue coverage at "COBRA" rates. Employees who lose their job as a
result of the acquisition who are age 50 and older upon termination of
employment shall be eligible to receive post-retirement medical and dental
benefits without regard to their number of years of service.

Other benefits will continue on the basis of existing terms and conditions.

Pfizer has agreed to maintain the comparable benefits for two years after the
merger.


Q: WHAT WILL HAPPEN TO RETIREE MEDICAL BENEFITS?
For two years following the close of the transaction, Pfizer has promised to
maintain comparable retiree medical, dental and life insurance benefits to those
Pharmacia offers, and for those who retire before the closing, Pfizer has
promised to maintain Pharmacia's retiree benefits with no change for at least
two years. After that, Pfizer has promised that if it alters this type of
benefit, it will replace it with benefits comparable to those it provides to its
own employees.


                                                                               6



Q: WILL I STILL RECEIVE MY 2002 INCENTIVE COMPENSATION?
A: If you remain employed through December 31, 2002, you will be eligible for a
full year incentive payment, which will be determined by company and individual
performance. If your employment is terminated prior to the end of the year, you
will receive a prorated incentive payment based on the greater of your incentive
target or forecasted year-end performance.


Q:  I HAVE STOCK OPTIONS.  WHAT WILL HAPPEN TO THEM?
A: For every Pharmacia option you hold after the spin-off of the Monsanto
agricultural subsidiary, you'll receive 1.4 options in Pfizer and have an
adjusted exercise price. Options will first need to be adjusted for the Monsanto
spin-off before an exact price calculation can be made. More information will be
communicated to you as it becomes available.


Q:  WILL MY STOCK OPTIONS VEST UPON THE CHANGE OF CONTROL TO PFIZER?
A: All options will vest upon shareholder approval of the transaction, whether
or not the merger actually closes.


Q: HOW LONG WILL I HAVE TO EXERCISE MY OPTIONS?
A: If you remain an employee, you will have the remainder of your full option
period to exercise your options. If you lose your job as a result of the
acquisition, you will have three years to exercise all options granted after the
merger of Pharmacia & Upjohn and Monsanto (effective April 1, 2000). For options
granted prior to the P&U and Monsanto merger, the provisions of the individual
grants will apply.


                                                                               7



Q: I'M FEELING QUITE STRESSED AS A RESULT OF THIS NEWS. DOES THE COMPANY OFFER
ANY PLACE I CAN TURN FOR HELP?

A: Please discuss your concerns with your supervisor or Human Resources
representative.

U.S. employees have the additional option of contacting the Pharmacia Employee
Assistance Program (EAP) for confidential help in dealing with personal issues.

If you live in Illinois, Wisconsin or west of the Mississippi River, call
Magellan Behavioral Health at 1-800-508-2422 or visit www.magellanassist.com
(the 800 number serves as the password).

If you live in the eastern United States (except Illinois or Wisconsin), call
Corporate Community Psychological Consultants (CCPC) at 1-877-768-3227 or
contact them at ECAP.Account@pharmacia.com.

More information on the EAP is available on the intranet at:

http://www-i.us.pnu.com/benefits/NEW/H&G/Other_Benefits/EAP.html


                                                                               8


- --------------------------------------------------------------------------------

                                   PHARMACIA

                             ACQUISITION BY PFIZER, INC.
                              POINTS FOR DISCUSSION

- --------------------------------------------------------------------------------

As all of you know by now, Pfizer, Inc. has announced to the public its
intention to acquire Pharmacia. We all have lots of questions about this news,
so I'd like to take a few moments to go through these discussion points with you
so that you have all the information that is available. At the end of this brief
slide deck, we'll take time for your questions and comments.




- --------------------------------------------------------------------------------

THE TRANSACTION FACTS

o  ON MONDAY, JULY 15, 2002, PFIZER ANNOUNCED ITS INTENTION TO ACQUIRE
   PHARMACIA.

o  THIS IS A MERGER TRANSACTION IN WHICH PFIZER IS EXPECTED TO ACQUIRE
   PHARMACIA. THIS IS NOT A MERGER OF EQUALS.

o  PFIZER IS PAYING A 52% PREMIUM ON PHARMACIA'S PHARMACEUTICAL STOCK PRICE. THE
   PREMIUM IS 44% BASED ON A 30-DAY BASIS.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

Here are the facts about the transaction.

On Monday, July 15, Pfizer announced its intention to acquire Pharmacia.

This is a merger transaction in which Pfizer is expected to acquire Pharmacia.
This is not a merger of equals.

Pfizer is paying a 52% premium on Pharmacia's pharmaceutical stock price. The
premium is 44% based on a 30-day basis.




- --------------------------------------------------------------------------------

THE TRANSACTION TIMELINE

o  PFIZER EXPECTS TO COMPLETE THE TRANSACTION LATE IN 2002.

o  PHARMACIA WILL SPIN-OFF MONSANTO AS SOON AS POSSIBLE.

o  PHARMACIA BENEFIT PROGRAMS AND EMPLOYMENT AGREEMENTS WILL BE HONORED UNDER
   THE TERMS OF THE MERGER AGREEMENT.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

Here is what we know about the transaction timeline today.

Pfizer has said it expects to complete the acquisition of Pharmacia late in
2002.

Pharmacia will spin-off the Monsanto agricultural subsidiary as soon as
possible. We expect to complete the spin-off before Pfizer acquires Pharmacia.

Right now we don't know the outcome of each individual employee as a result of
the acquisition. Most people will continue in their roles. Others may change
their roles - or there may not be a role for them. It is important to keep in
mind that, as of now, all of the Pharmacia benefit programs and employment
agreements will be honored under the terms of the merger agreement.




- --------------------------------------------------------------------------------

THE RATIONALE FOR PHARMACIA'S DECISION:
SITUATION ANALYSIS

o  ALTHOUGH PHARMACIA HAS DONE WELL, THIS YEAR THE COMPANY WAS FACED WITH
   UNUSUAL CHALLENGES AND UNPRECEDENTED CHANGE IN THE INDUSTRY.

o  SENIOR LEADERS CONSIDERED A NUMBER OF STRATEGIC OPTIONS TO MAXIMIZE VALUE.

o  THEN PFIZER MADE AN OFFER SO COMPELLING, OUR LEADERS CONCLUDED WE SHOULD
   ACCEPT IT.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

Everybody at Pharmacia is asking the same question: "WHY?" To
understand why our leaders agreed to an acquisition, we need to
understand their analysis of Pharmacia's situation.

At Pharmacia, we have uniquely molded an amalgam of diverse smaller and weaker
companies into an aligned, high-performance global competitor.

Pharmacia's senior leaders considered a number of strategic options to get the
most from our existing medicines and our pipeline, and to maximize value for our
shareholders.

However, recent growing pressures in our industry have caused all large
companies to re-think their business models. In the past, we had rejected
informal approaches from various companies. When Pfizer recently approached us
with an offer that we viewed as compelling for our shareowners, we concluded
that we should accept it.



- --------------------------------------------------------------------------------

THE RATIONALE FOR PHARMACIA'S DECISION:
TWO MAJOR REASONS

o  PFIZER IS THE BEST STRATEGIC FIT AND LONG-TERM PARTNER FOR OUR STRENGTHS.
   THE TWO COMPANIES' PRODUCT LINES AND PIPELINES ARE COMPLEMENTARY. THE
   COMBINED COMPANY CREATES A PREEMINENT PHARMA INDUSTRY LEADER. THIS IS GOOD
   FOR CUSTOMERS, PATIENTS AND FUTURE MEDICAL INNOVATION.

o  THE DEAL PROVIDES SIGNIFICANT VALUE FOR PHARMACIA SHAREHOLDERS. IT REFLECTS
   THE EXCEPTIONAL VALUE WE BUILT IN THE COMPANY.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

There were two major reasons that Pharmacia leaders decided to accept Pfizer's
offer.

First, Pfizer is the best strategic fit and long-term partner for our existing
strengths. We already co-market our COX-2 products with them, so we have a
history of cooperation and mutual respect. The two companies' product lines and
pipelines are complementary. The combined company creates a preeminent pharma
industry leader. That's good for our customers and for patients. And it gives us
exceptional strength for future medical innovation, something to which we have
been deeply committed - even in our heritage companies.

Second, the deal provides significant value for our shareholders. That includes
employees who own Pharmacia shares, too. Pfizer's offer reflects the exceptional
value we built in the company.



- --------------------------------------------------------------------------------

THE TRANSACTION IMPACT: BUSINESS

o  PHARMACIA CHAIRMAN AND CEO FRED HASSAN WILL BECOME VICE CHAIRMAN OF PFIZER,
   INC.

o  AT THIS TIME, WE DO NOT KNOW HOW THE INTEGRATION OF PHARMACIA AND PFIZER WILL
   UNFOLD.

o  PHARMACIA LEADERS WILL KEEP EMPLOYEES INFORMED AS DECISIONS ARE MADE.

o  IN SPITE OF THE ANTICIPATED CHANGE, IT IS "BUSINESS AS USUAL" AT PHARMACIA.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

Obviously, the acquisition will have an impact on Pharmacia's business. We know
that Fred Hassan will become Vice Chairman of Pfizer. We do not know about other
Pharmacia leaders' roles at this time.

Because it is so early in the process, we do not know how the integration of
Pharmacia and Pfizer will unfold.

However, Pharmacia leaders have pledged to keep all employees informed as
decisions are made and they are able to announce them.

Even though Pharmacia may become part of Pfizer late in 2002, our leadership
team is asking us to continue business as usual in our company.

I recognize how difficult that will be for us - but for the sake of Pharmacia
customers and the patients our products help, we really do have to stay the
course and continue our work. This is going to be a months-long transition, and
the best thing we can do is stay focused on the work that matters.



- --------------------------------------------------------------------------------

THE TRANSACTION IMPACT: EMPLOYEES

o  THERE WILL BE NO IMMEDIATE CHANGES OR IMPACTS ON EMPLOYEES.

o  WE MUST REMAIN FOCUSED ON OUR CURRENT TASKS FOR THE GOOD OF OUR CUSTOMERS AND
   OUR PATIENTS.

o  WE WILL MAINTAIN CURRENT REPORTING RELATIONSHIPS.

o  WE WILL CONTINUE TO OBSERVE SMART INITIATIVE POLICIES AND COST CONSCIOUSNESS
   REQUIREMENTS.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

I think the natural response of most people when they hear news like this is to
wonder: "What's going to happen to me?" I wish I could give you a lot of details
about what you can expect, but at this point in the transition, those details
that we are all concerned about are just not known.

Here is what I can tell you:

oThere are no immediate changes or impacts on employees planned.

oAs we just noted, we must remain focused on our current tasks for the good of
our customers and patients.

oWe will maintain our current reporting relationships.

oAnd we will continue tobserve the SMART initiative policies that were enacted
earlier this month as well as the cost consciousness requirements that were
announced a few months ago. That means the hiring hold is still in effect.
Restrictions on travel and catering will continue. And we will abide by the new
policies related to contract workers, consultants and meetings.



- --------------------------------------------------------------------------------

THE REALITIES OF AN ACQUISITION

o  AN ACQUISITION SIGNALS A CHANGE IN CONTROL. UNCERTAINTY IS PART OF CHANGE.

o  PHARMACIA CANNOT DIRECT THE ULTIMATE STRATEGIES AND DECISIONS MADE ABOUT OUR
   COMPANY.

o  PHARMACIA LEADERS ARE COMMITTED TO COMMUNICATING WITH EMPLOYEES THROUGHOUT
   THE TRANSITION AS DECISIONS ARE MADE AND ANNOUNCED.

o  THE MEDIA WILL REPORT AND COMMENT ON THE DEAL. SOME OF THOSE COMMENTS COULD
   CONTAIN SPECULATION AND ERRORS, DESPITE EFFORTS TO PROVIDE CLEAR INFORMATION.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

In the spirit of Best-Managed Behaviors, I feel we need to be very honest in our
discussions and look at the realities of any acquisition - including this one.

An acquisition means that there will be a change in control. Uncertainty about
the future is part of the change we can expect.

Now that Pharmacia has agreed to be acquired by Pfizer, we no longer direct the
ultimate strategies and decisions made about our company.

Pharmacia leaders have committed themselves to communicating with us during the
transition as decisions are made and announced.

And we have to expect that the media will report and comment on the deal. Please
be aware that some of that commentary could contain speculation and errors,
despite our efforts to provide clear information.



- --------------------------------------------------------------------------------

OUR GO-FORWARD STRATEGY

o  KEEP DOING OUR JOBS WELL.

o  CONTINUE TO LIVE BY THE BEST-MANAGED BEHAVIORS.

o  TAKE A POSITIVE ATTITUDE AND BE EMPATHETIC TO PEOPLE.

o  RESIST UNPRODUCTIVE CONDUCT SUCH AS COMPLAINING OR GRIDLOCK.

                                                                       PHARMACIA
- --------------------------------------------------------------------------------

It's easy to become discouraged or demotivated during an acquisition. But
Pharmacia people are accustomed to change and are energized by it.

Pharmacia's go-forward strategy during this transition involves four key steps:

Keep doing our jobs well - customers and patients are counting on us.

Continue to live by the Best-Managed Behaviors.

Take a positive attitude about the changes ahead and empathize with people
around us.

Resist unproductive conduct such as turning discussion into complaining or
allowing programs and actions to become gridlocked by indecision.




- --------------------------------------------------------------------------------

                                   PHARMACIA

                          ACQUISITION BY PFIZER, INC.
                              QUESTIONS & Answers

- --------------------------------------------------------------------------------


With that in mind, I'd like to open up our discussion to give you the chance to
ask questions and make comments. I will do the best I can in answering your
questions, however, much remains to be learned as the transaction unfolds over
these next few months.

I understand that many of you may feel shocked and angry about the decision to
be acquired by Pfizer. Some of you might even feel betrayed by Pharmacia and its
leaders. I think it's normal to feel this way.

While I'm willing to hear whatever you have to say, I'd like to use this time
together to build understanding of the news and begin finding solutions for how
we will work as a team during the transition.

Who would like to ask the first question?



                           FORWARD-LOOKING INFORMATION

Certain statements contained in this document are "forward-looking statements"
provided under the "safe harbor" protection of the Private Securities Litigation
Reform Act of 1995. These statements are made to enable a better understanding
of the Company's business, but because these forward-looking statements are
subject to many risks, uncertainties, future developments and changes over time,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Examples of forward-looking statements are
statements about anticipated financial or operating results, financial
projections, business prospects, future product performance, future research and
development results, anticipated regulatory filings and approvals, and other
matters that are not historical facts. Such statements often include words such
as: "believes", "expects", "anticipates", "intends", "plans", "estimates", or
similar expressions.

These forward-looking statements are based on the information that was currently
available to the Company, and the expectations and assumptions that were deemed
reasonable by the Company, at the time when the statements were made. The
Company does not undertake any obligation to update any forward-looking
statements in this Report or in any other communications of the Company, whether
as a result of new information, future events, changed assumptions or otherwise,
and all such forward-looking statements should be read as of the time when the
statements were made, and with the recognition that these forward-looking
statements may not be complete or accurate at a later date.

Many factors may cause or contribute to actual results or events being
materially different from those expressed or implied by such forward-looking
statements. Although it is not possible to predict or identify all such factors,
they may include the following: competition for our products; pharmaceutical
pricing, price constraints and other restrictions on the marketing of products
imposed by governmental agencies or by managed care groups, institutions and
other purchasing agencies; product discovery and approval; product recalls or
withdrawals; manufacturing quality issues with respect to our products;
compliance with Current Good Manufacturing Practices and other applicable
regulations and quality assurance guidelines; the company's ability to secure
and defend its intellectual property rights; product liability claims, antitrust
litigation, environmental concerns, and commercial disputes; social, legal,
political and governmental developments; changes in foreign currency exchange
rates or in general economic or business conditions including inflation and
interest rates; acquisitions, divestitures, mergers, restructurings or strategic
initiatives that change the Company's structure; business combinations among the
Company's competitors and major customers; changes to accounting standards or
GAAP.

Readers are also urged to carefully review and consider the various disclosures
in Pharmacia's various SEC filings, including but not limited to Pharmacia's
Annual Report on Form 10-K for the year ended December 31, 2001, and Pharmacia's
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2002.

This release may be deemed to be solicitation material in respect of Pfizer's
proposed merger with Pharmacia. Pfizer will be filing a registration statement
on Form S-4, containing a joint proxy statement/prospectus for Pfizer and
Pharmacia, and other documents with the Securities and Exchange Commission
("SEC"). INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE REGISTRATION
STATEMENT CONTAINING THE JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT
DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders
will be able to receive the registration statement containing the joint proxy
statement/prospectus and other documents free of charge at the SEC's web site,
www.sec.gov or from Pharmacia Investor Relations at 100 Route 206 North,
Peapack, New Jersey 07977. Pharmacia and its directors and executive officers
and other members of management and employees may be deemed to be participants
in the solicitation of proxies in respect of the proposed transaction.
Information regarding the interests of Pharmacia's directors and executive
officers in the proposed merger will be included in the final joint proxy
statement/prospectus.